Substance |
Cell |
Chemerin |
Ref |
Substance |
CMKLR1 |
Ref |
IL-6 50 ng/ml |
PHH |
mRNA ↔ |
[21] |
IL-6 50 ng/ml |
mRNA ↑ |
[21] |
IL-6 5, 20 ng/ml |
PHH |
CP, SN ↔ |
[13] |
IL-6 5 ng/ml |
CP ↔ |
[14] |
IL-6 |
Hep3B |
mRNA ↔ |
[27] |
|
|
|
|
|
|
|
|
|
|
IL-1beta 10 ng/ml |
Hep3B |
mRNA ↔, SN ↓ |
[27] |
|
|
|
|
|
|
|
|
|
|
Glucagon 100 nM |
PHH |
mRNA ↔ |
[21] |
Glucagon 100 nM |
mRNA ↔ |
[21] |
Insulin 100 nM |
PHH |
mRNA ↔ |
[21] |
Insulin 100 nM |
mRNA ↔ |
[21] |
Palmitate 0.3 mM |
PHH |
mRNA ↔ |
[21] |
Palmitate 0.3 mM |
mRNA ↔ |
[21] |
Palmitate 0.3 mM |
PHH |
CP ↔, SN (↓) |
[12] |
Palmitate 0.3 mM |
mRNA, CP ↔ |
[14] |
Oleate 0.3 mM |
PHH |
CP, SN ↔ |
[12] |
Oleate 0.3 mM |
mRNA, CP ↔ |
[14] |
Palmitate 0.1, 0.2, 0.5 mM |
HepG2 |
mRNA, SN ↓ |
[26] |
|
|
|
FXR agonist 1, 2, 5 µM |
HepG2 |
mRNA ↑ |
[26] |
|
|
|
FXR agonist 1, 2, 5 µM |
PMH |
mRNA ↑ |
[26] |
|
|
|
LXR agonist |
HepG2 |
mRNA ↔ |
[26] |
|
|
|
PPARg agonist |
HepG2 |
mRNA ↔ |
[26] |
|
|
|
PPARa agonist |
HepG2 |
mRNA ↔ |
[26] |
|
|
|
Leptin 20 ng/ml |
PHH |
CP ↔, SN ↑ |
[13] |
Leptin 10, 20 ng/ml |
CP ↔ |
[14] |
TNFa 2 ng/ml |
PHH |
CP ↔, SN ↓ |
[13] |
TNFa 0.5, 2 ng/ml |
CP ↔ |
[14] |
TNFa 25 ng/ml |
Hep3B |
mRNA, SN ↔ |
[27] |
|
|
|
TNFa 20 ng/ml |
PMH |
CP ↔ |
[12] |
|
|
|
TGFβ5 ng/ml |
PHH |
CP ↔, SN ↑ |
[13] |
TGFβ 5 ng/ml |
CP (↓) |
[14] |
APN 10 µg/ml |
PHH |
CP ↔, SN ↓ |
[13] |
APN 10 µg/ml |
mRNA, CP ↑ |
[14] |
LPS10 µg/ml |
PHH |
CP, SN ↔ |
[13] |
LPS 1, 10 µg/ml |
CP ↔ |
[14] |
|
PHH |
|
|
ACAT Inh + AcLDL |
CP ↔ |
[14] |
Metformin 0.5, 1 mM |
PHH |
CP, SN ↓ |
[13] |
|
|
|
Aspirin 2, 20 mg/l |
Hep3B |
mRNA, SN ↔ |
[27] |
|
|
|
|
Acetylated LDL, AcLDL; adiponectin, APN; cellular protein, CP; farnesoid X receptor, FXR; liver X receptor, LXR; primary human hepatocytes, PHH; primary mouse hepatocytes, PMA; Inhibitor, Inh; peroxisome proliferator-activated receptor, PPAR; reference, Ref; supernatant, SN; not regulated, ↔; pregulated, ↑; downregulated, ↓;
when arrows are given in brackets this indicates a trend. |